Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
https://finance.yahoo.com/news/aptevo-th...00684.html
The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Nov. 9)....
Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
Mon, November 9, 2020, 12:00 PM
Second Complete Remission Observed in a Patient in Cohort 6
Enrollment in Cohort 8 Has Started
SEATLLE, WA / ACCESSWIRE / November 9, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ platform, today provided an update on its ongoing APVO436 Phase 1 clinical trial.
APVO436 is a novel anti-CD123 x anti-CD3 targeted investigational bispecific antibody therapy being evaluated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), in a Phase 1/1b open-label, dose-escalation study evaluating the safety and pharmacokinetic profile.
On Friday, November 6, Aptevo received preliminary data regarding cohort 6, which indicated complete remission in a second patient, in addition to the one previously announced. In total, there are now two patients with clinical remission in cohort 6. The data received also showed one patient exhibiting stable disease status, and six patients where the disease had progressed. A total of nine patients were listed in cohort 6 of the clinical trial......
https://finance.yahoo.com/news/aptevo-th...00458.html
https://finance.yahoo.com/news/aptevo-th...00684.html
The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Nov. 9)....
- Aptevo Therapeutics Inc (NASDAQ: APVO) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients)
Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
Mon, November 9, 2020, 12:00 PM
Second Complete Remission Observed in a Patient in Cohort 6
Enrollment in Cohort 8 Has Started
SEATLLE, WA / ACCESSWIRE / November 9, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ platform, today provided an update on its ongoing APVO436 Phase 1 clinical trial.
APVO436 is a novel anti-CD123 x anti-CD3 targeted investigational bispecific antibody therapy being evaluated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), in a Phase 1/1b open-label, dose-escalation study evaluating the safety and pharmacokinetic profile.
On Friday, November 6, Aptevo received preliminary data regarding cohort 6, which indicated complete remission in a second patient, in addition to the one previously announced. In total, there are now two patients with clinical remission in cohort 6. The data received also showed one patient exhibiting stable disease status, and six patients where the disease had progressed. A total of nine patients were listed in cohort 6 of the clinical trial......
https://finance.yahoo.com/news/aptevo-th...00458.html